Lynparza Rejection Highlights ‘Two-Tier’ Funding Problem In UK
Too Many Uncertainties, Price Not Justified, Says NICE
Executive Summary
Health technology assessment body NICE has said that Lynparza from AstraZeneca and MSD is not a cost-effective use of National Health Service resources in England for prostate cancer patients at the price at which it is currently being offered. AZ and NICE say they will try to reach an agreement.
You may also be interested in...
Trial Population Was One Reason For Pulling Surufatinib EU Filing
Hutchmed is in discussions with the European Medicines Agency on the path forward for its drug for advanced neuroendocrine tumors, whose marketing authorization application has now been withdrawn.
New Zealand Extends Deadline For Opioid Risk Warning
Medsafe has taken on board industry’s request for more time to implement its new labeling requirement for medicines containing opioids.
Advanced Therapy Developers Urged To Monitor Major EU Proposal On Using Blood, Tissues & Cells
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.